Please login to the form below

Farxiga

This page shows the latest Farxiga news and features for those working in and with pharma, biotech and healthcare.

That growth was led by an increase in revenue for AZ’s heart failure treatment Farxiga (dapagliflozin), which saw a 27% increase in 2020 to $1.96bn.

Bayer’s finerenone scores FDA priority review for chronic kidney disease

In September 202 0, AstraZeneca announced that its SGLT2 inhibitor Farxiga (dapagliflozin) plus standard of care reduced the risk of cardiovascular or renal death and worsening of renal function by 39% ... Earlier this year, Farxiga also won a priority
Amgen, Cytokinetics’ heart failure drug disappoints in phase 3

This includes Novartis’ Entresto (sacubitril/valsartan) and AstraZeneca’s Farxiga (dapagliflozin) which have been steadily adding indications to their labels since initial approval.
AZ’s Farxiga cuts risk of death in chronic kidney disease

AstraZeneca (AZ) has revealed some impressive results from a phase 3 study of its heart failure drug Farxiga in chronic kidney disease (CKD) at the European Society of Cardiology (ESC) virtual ... The results from this study are not likely to be
Boehringer/Lilly's Jardiance hits the mark in pivotal heart failure trial

This includes AstraZeneca’s Farxiga (dapagliflozin), which became the first drug in the SGLT2 inhibitor class to be approved in the US to reduce the chance of hospitalisations, in adults with ... Earlier this week, AZ also touted results for Farxiga in
AstraZeneca escapes pandemic impact as new drugs bolster revenues

Over in its CVRM franchise, total revenue reached $2.26bn thanks to strong sales of its heart failure med Farxiga (dapagliflozin) and Brilinta (ticagrelor).

More from news
Approximately 13 fully matching, plus 42 partially matching documents found.

20 for 2020 – Five pharma companies to watch

Diabetes therapy Farxiga (dapagliflozin) has the potential to go where no other drug in the SGLT2 inhibitor class has gone before as it secures approval for heart failure in both diabetic
China: AstraZeneca’s new engine for growth and innovation

One of its latest launches in the country is Farxiga, its contender in the SGLT2 inhibitor diabetes market.
Transforming times at AstraZeneca

and was the pharma company with the most approvals from the US FDA with four last year, including the diabetes drug Farxiga (dapagliflozin) and Lynparza (olaparib) for ovarian cancer.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

Add my company

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Good design saves lives: Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies: Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...
A cultural shift in clinical research: Research organisations across the board are experimenting with new technologies...